Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.

by Garrick D Talmage, Oscar J M Coppes, Adil Javed, Jacqueline Bernard
Published 2017-01-01

Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.

by Garrick D Talmage, Oscar J M Coppes, Adil Javed, Jacqueline Bernard
Published 2017-01-01

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

by Fredrika Koskimäki, Jacqueline Bernard, Jeong Yong, Nancy Arndt, Timothy Carroll, Seon-Kyu Lee, Anthony T Reder, Adil Javed
Published 2018-01-01

In vitro cytotoxic and antimicrobial activities of Erythrina suberosa (Roxb) bark

by Zubair Ahmed, Sohail Aziz, Syed Alauddin, Syed Ghouse Mohiuddin, Adil Javed, Rizwan Ahmed, Ahmad Naoras Bitar, Siti Maisharah Sheikh Ghadzi
Published 2020-01-01

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.

by Anza B Memon, Adil Javed, Christina Caon, Shitiz Srivastawa, Fen Bao, Evanthia Bernitsas, Jessica Chorostecki, Alexandros Tselis, Navid Seraji-Bozorgzad, Omar Khan
Published 2018-01-01

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

by Wendy Gilmore, Brett T. Lund, Peili Li, Alex M. Levy, Eve E. Kelland, Omid Akbari, Susan Groshen, Steven Yong Cen, Daniel Pelletier, Leslie P. Weiner, Adil Javed, Jeffrey E. Dunn, Anthony L. Traboulsee
Published 2020-06-01